We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

25 hedge funds and large institutions have $12.7M invested in Oruka Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

94% more capital invested

Capital invested by funds: $6.55M → $12.7M (+$6.16M)

19% more funds holding

Funds holding: 21 → 25 (+4)

2.44% more ownership

Funds ownership: 1.88% → 4.32% (+2.4%)

Holders
25
Holders Change
+4
Holders Change %
+19.05%
% of All Funds
0.36%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
5
Increased
6
Reduced
3
Closed
1
Calls
$37K
Puts
–
Net Calls
+$37K
Net Calls Change
-$42K

Top Buyers

Rank Fund Capital Flow
1
WSL
Western Standard LLC
California
+$441K
2
Aberdeen Group
Aberdeen Group
United Kingdom
+$60.7K
3
TSS
Two Sigma Securities
New York
+$22.7K
4
Renaissance Technologies
Renaissance Technologies
New York
+$12.2K
5
Citadel Advisors
Citadel Advisors
Florida
+$11.8K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$94.4K
2
NM
Newtyn Management
New York
-$57.4K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.26K
4
BlackRock
BlackRock
New York
-$90
Name Holding Trade Value Shares
Change 		Change in
Stake
CCC
1
Cable Car Capital
California
$6.8M +$7.49M +333,371 New
WSL
2
Western Standard LLC
California
$2.4M +$441K +19,656 +20%
BCM
3
BML Capital Management
Indiana
$1.2M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$771K +$5.73K +255 +0.7%
NM
5
Newtyn Management
New York
$458K -$57.4K -2,557 -10%
BlackRock
6
BlackRock
New York
$394K -$90 -4 -0%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$242K – – –
State Street
8
State Street
Massachusetts
$121K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$97K +$12.2K +542 +13%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$72.3K – – –
Aberdeen Group
11
Aberdeen Group
United Kingdom
$55.2K +$60.7K +2,705 New
Northern Trust
12
Northern Trust
Illinois
$35.7K – – –
Charles Schwab
13
Charles Schwab
California
$25.5K – – –
TSS
14
Two Sigma Securities
New York
$20.6K +$22.7K +1,010 New
Citadel Advisors
15
Citadel Advisors
Florida
$10.7K +$11.8K +527 New
TRCT
16
Tower Research Capital (TRC)
New York
$5.14K -$1.26K -56 -18%
UBS Group
17
UBS Group
Switzerland
$1.92K +$1.89K +84 +840%
PA
18
Parallel Advisors
California
$415 – – –
Wells Fargo
19
Wells Fargo
California
$134 +$22 +1 +17%
Osaic Holdings
20
Osaic Holdings
Arizona
$93 – – –
Qube Research & Technologies (QRT)
21
Qube Research & Technologies (QRT)
United Kingdom
$85 – – –
Bank of America
22
Bank of America
North Carolina
$73 +$22 +1 +33%
JP Morgan Chase
23
JP Morgan Chase
New York
$27 – – –
BCM
24
Bridgeway Capital Management
Texas
– -$94.4K -3,912 Closed
Simplex Trading
25
Simplex Trading
Illinois
– +$180 +8 New

ORKA Hedge Fund Activity: Q4 2023 in Review

25 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2023, worth a combined $12.7M — up 94% from $6.55M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ORKA positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 3 trimmed.

The largest buyer was Western Standard LLC, adding an estimated $441K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $94.4K sold.

  • 25 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2023, up from 21 in Q3 2023.
  • Funds reported $12.7M of Oruka Therapeutics stock for Q4 2023, up 94% quarter-over-quarter.
  • 5 funds opened new Oruka Therapeutics positions in Q4 2023 and 1 closed out, a net change of +4 holders.
  • The largest Oruka Therapeutics buyer in Q4 2023 was Western Standard LLC, an estimated $441K added.
  • The largest Oruka Therapeutics seller in Q4 2023 was Bridgeway Capital Management, an estimated $94.4K sold.

Based on aggregated 13F filings for Q4 2023.